Skip to main content

Prototype Prescribing Outlier Dashboard for Moreton Cross Group Practice

At OpenPrescribing we are piloting a number of data-driven approaches to identify unusual prescribing and collect feedback on this prescribing to inform development of new tools to support prescribers and organisations to audit and review prescribing. These pilot results are provided for the interest of advanced users, although we don't know how relevant they are in practice. There is substantial variation in prescribing behaviours, across various different areas of medicine. Some variation can be explained by demographic changes, or local policies or guidelines, but much of the remaining variation is less easy to explain.

The DataLab is keen to hear your feedback on the results. You can do this by completing the following survey or emailing us at [email protected]. Please DO NOT INCLUDE IDENTIFIABLE PATIENT information in your feedback. All feedback is helpful, you can send short or detailed feedback.

This report has been developed to automatically identify prescribing patterns at a chemical level which are furthest away from “typical prescribing” and can be classified as an “outlier”. We calculate the number of prescriptions for each chemical in the BNF coding system, the count of all prescriptions within that chemical's BNF subparagraph, for prescriptions dispensed between June 2021 and December 2021. We then calculate the ratio of these counts along with the mean and standard deviation of those ratios across all Practices. From this we can calculate the “z-score”, which is a measure of how many standard deviations a given Practice is from the population mean. We then rank your “z-scores” to find the top 10 results where prescribing is an outlier for prescribing higher than its peers and those where it is an outlier for prescribing lower than its peers.

For each outlier chemical, a kernel density estimation plot of all Practice's chemical:subparagraph ratios is provided, with this Practice's ratio overlaid in red.

It is important to remember that this information was generated automatically and it is therefore likely that some of the behaviour is warranted. This report seeks only to collect information about where this variation may be warranted and where it might not, to inform research on this topic. Our full analytical method code is openly available on GitHub here.

This is a new, experimental feature. We'd love to .

Prescribing where Moreton Cross Group Practice is higher than most

BNF Chemical Chemical Items BNF Subparagraph Subparagraph Items Ratio Mean std Z_Score Plots
Celecoxib 353 Non-steroidal anti-inflammatory drugs 1,459 0.24 0.03 0.04 5.78
Felodipine 1,484 Calcium-channel blockers 2,677 0.55 0.08 0.08 5.68
Mycophenolic sodium 7 Antiproliferative immunosuppressants 55 0.13 0.01 0.03 4.72
Prednisolone acetate 19 Corticosteroids 24 0.79 0.15 0.16 4.03
Sodium chloride 9 Electrolytes and water 9 1.00 0.17 0.24 3.39
Dexamethasone phosphate 9 Use of corticosteroids 702 0.01 0.00 0.00 3.15
Patiromer calcium 5 Oral potassium 23 0.22 0.01 0.07 2.96
Pentoxifylline 4 Peripheral vasodilators and related drugs 4 1.00 0.15 0.30 2.88
Disopyramide phosphate 6 Drugs for arrhythmias 96 0.06 0.00 0.02 2.83
Magnesium citrate 2 Magnesium 3 0.67 0.07 0.21 2.82

Prescribing where Moreton Cross Group Practice is lower than most

BNF Chemical Chemical Items BNF Subparagraph Subparagraph Items Ratio Mean std Z_Score Plots
Amlodipine 920 Calcium-channel blockers 2,677 0.34 0.76 0.11 -3.66
Water for injection 0 Electrolytes and water 9 0.00 0.82 0.25 -3.33
    Vitamin A 0 Vitamin A 7 0.00 0.82 0.36 -2.28
      Dexamethasone 0 Corticosteroids 24 0.00 0.49 0.22 -2.19
        Neomycin sulfate 24 Nasal preparations for infection 43 0.56 0.84 0.14 -2.03
        Losartan potassium 274 Angiotensin-II receptor antagonists 1,867 0.15 0.50 0.19 -1.91
        Naftidrofuryl oxalate 0 Peripheral vasodilators and related drugs 4 0.00 0.67 0.39 -1.73
          Senna 227 Stimulant laxatives 725 0.31 0.55 0.14 -1.72
          Citalopram hydrobromide 756 Selective serotonin re-uptake inhibitors 4,324 0.17 0.32 0.08 -1.71
          Hydroxychloroquine sulfate 29 Rheumatic disease suppressant drugs 267 0.11 0.37 0.16 -1.67